Libidon®
Biologically active food supplement LIBIDON® contains a complex of low molecular weight peptides
with a molecular weight of up to 5000 Da, isolated from the tissues of the triceps muscle of young
animals - mature bulls.
LIBIDON® is available in the form of capsules with an active substance content of 10 mg.
LIBIDON® peptides regulate metabolic processes in the prostate gland cells, increase their reserve
capacity, have a beneficial effect on the adaptation processes of the body in extreme conditions, have
antioxidant properties, and regulate the processes of peroxidation in the tissues of the prostate. Ex-
perimental studies have shown that peptides have a tissue-specific effect on the cells of those tissues
from which they are isolated. This allows us to assume the effectiveness of the use of LIBIDON® to
restore the functions of the prostate gland in men of different ages with disorders of various origins.
Diseases of the prostate gland currently occupy an important place among urological pathology, tend to
increase the incidence, and acquire an ever-increasing social significance (1, 3). According to a number
of authors, more than 70% of men over the age of 50 suffer from prostate diseases, including benign
prostatic hyperplasia and oncological diseases. Thus, the search for new effective and safe agents for
preventing and treating prostate diseases is an urgent task.
In the conservative treatment of patients with prostate diseases, taking into account the pathoge-
netic mechanisms, the following traditional drugs of various directions of action are mainly used (2):
- Antibacterial and anti-inflammatory action - antibiotics and sulfa drugs;
- Normalization of microcirculation - trental, galidor, escuzan;
- Stimulation of metabolic processes - streptokinase, raveron;
- Antispasmodic action - no-shpa, baralgin;
- Normalization of the level of sex hormones - methyltestosterone, sustanon-250;
- Correction of immunopathological reactions - prodigiosan, pyrogenal, levamisole, tavegil, fenkarol.
- etc.
CLINICAL CHARACTERISTICS OF PATIENTS
A clinical study of the effectiveness of the use of LIBIDON®was carried out at the Medical Center of
the St. Petersburg Institute of Bioregulation and Gerontology in the period from March to November
2011.
Distribution of patients by nosological forms and age. Table 1
Diagnosis Age Number of Patients
Chronic prostatitis 38-49 28
Benign prostatic hyperplasia 51-65 20
Total: 48
* p <0.05 - significant compared with the indicator before treatment;
# p <0.05 - significant compared with the indicator in patients of the control group.
Clinical trials were carried out in 48 patients aged 38 to 65 years with a diagnosis of benign prostatic
hyperplasia (BPH) and chronic prostatitis (Table 1), who, in addition to conventional therapy, were
prescribed LIBIDON®: orally 1 capsule 2 times a day with meals for 30 days. The control groups
consisted of 22 similar patients who received only conventional treatment.
RESEARCH METHODS
The effectiveness of treatment was assessed based on the dynamics of patients’ complaints, general
clinical examination of blood and urine, biochemical blood study on the REFLOTRON apparatus
(Boehringer Mannheim, Germany), and blood coagulograms before and after the end of treatment.
Using the device «UROFLOUKOMPAKT» (Wiest, Germany), the maximum, average rate and time of
urination, the time to reach the maximum rate of urination, and the fluorometric index were assessed.
The degree of abdominal pressure during urination and the nature of the urine stream was expressed
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.